Participants Flow



Baseline Characteristics

Table 1: Baseline Characteristics

Demographic and Baseline Variable	Statistics	Gantenerumab 510 mg (N=20)
Age (years)	n Mean Standard Deviation [SD]	20 33.5 8.48
Sex (percentage of participants) Male Female	 n (%) n (%)	 11 (55.0) 9 (45.0)

cm=centimetres; kg= kilograms; kg/m^2=kilograms per metre square; mm= millimetres;

Outcome measures

Primary Outcome Measures:

1. Plasma concentration (Cmax) of gantenerumab measured using enzyme-linked immunosorbent assay (ELISA) at pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 8, 12, 21, 29, 43, 64 and 85

   Analysis Population: Pharmacokinetic analysis population (PKAP) included all participants who received a single subcutaneous (SC) dose of gantenerumab and who had evaluable PK data with no relevant protocol deviations with respect to the PK endpoints

   Table 2: Summarized Gantenerumab Cmax

Treatment	Number of Participants Analysed	Geometric Mean	Geometric Coefficient of Variation
Cmax	20	39.72	55.94

   Unit of measurement: micrograms per millilitre (µg/mL)

2. Area under the concentration–time curve of gantenerumab measured using noncompartmental analysis from time 0 to infinity (AUC[0-inf]) at pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 8, 12, 21, 29, 43, 64 and 85

   Analysis Population: PKAP included all participants who received a single SC dose of gantenerumab and who had evaluable PK data with no relevant protocol deviations with respect to the PK endpoints

   Table 3: Summarized Gantenerumab AUC(0-inf)

Treatment	Number of Participants Analysed	Geometric Mean	Geometric Coefficient of Variation
AUC(0-inf)	19	21620	40.13

   Unit of measurement: micrograms*hour per millilitre (µg*h/mL)

3. Nature, incidence, severity, and causal relationship of adverse events (AEs) recorded through case report form (CRF) during the AE reporting period (defined as from screening to 85 days after the dose of study drug)

   Analysis Population: Safety analysis population (SAP) included all participants who received at least 1 dose of gantenerumab, whether or not they had prematurely withdrawn from the study

   Table 4: Overview of Adverse Events

	Gantenerumab 510 mg (N=20) n (%)
AEs	16 (80.0)
AE by Most Extreme Severity	
Severe	0
Moderate	0
Mild	16 (80.0)
Serious AE	0
AE by Maximum Relationship to IMP*	
Related	13 (65.0)
Not related	3 (15.0)

*IMP= Investigational Medicinal Product
Unit of measurement: participants

4. Local pain assessed using the Visual Analog Scale (VAS) at the following timepoint: after first needle insertion, immediately post-dose (second injection), 5 minutes, 10 minutes, 20 minutes, 1 hour, 6 hours, 24 hours and 48 hours post-dose (and at additional regular intervals at the investigator's discretion if an adverse reaction associated with local tolerability and pain is observed)

Analysis Population: SAP included all participants who received at least 1 dose of gantenerumab, whether or not they had prematurely withdrawn from the study

Table 5: Pain Visual Analogue Scale

Timepoints	**Number of Participants Analysed**	**Statistics**	**Gantenerumab 510 mg (N=20)**
After first needle insertion	20	Mean SD	10.5 7.86
Immediately post-dose (second injection)	20	Mean SD	18.7 14.21
5 minutes post-dose	20	Mean SD	2.7 5.69
10 minutes post-dose	20	Mean SD	0.9 2.65
20 minutes post-dose	20	Mean SD	0.6 1.19
1 hour post-dose	20	Mean SD	0.0 0.00
6 hours post-dose	20	Mean SD	0.0 0.00
24 hours post-dose	20	Mean SD	0.0 0.00
48 hours post-dose	20	Mean SD	0.1 0.22

Unit of measurement: units on a scale

5. Local pain assessed using the Pain Verbal Rating Scale (VRS) at the following timepoint: after first needle insertion, immediately post-dose (second injection), 5 minutes, 10 minutes, 20 minutes, 1 hour, 6 hours, 24 hours and 48 hours post-dose (and at additional regular intervals at the investigator's discretion if an adverse reaction associated with local tolerability and pain is observed)

   Analysis Population: SAP included all participants who received at least 1 dose of gantenerumab, whether or not they had prematurely withdrawn from the study

   Table 6: Pain Verbal Rating Scale

Timepoints	Number of Participants Analysed	Statistics	Gantenerumab 510 mg (N=20)
After first needle insertion	20	Mean SD	0.8 0.52
Immediately post-dose (second injection)	20	Mean SD	1.7 0.75
5 minutes post-dose	20	Mean SD	0.3 0.57
10 minutes post-dose	20	Mean SD	0.2 0.37
20 minutes post-dose	20	Mean SD	0.1 0.31
1 hour post-dose	20	Mean SD	0.0 0.00
6 hours post-dose	20	Mean SD	0.0 0.00
24 hours post-dose	20	Mean SD	0.0 0.00
48 hours post-dose	20	Mean SD	0.0 0.00

   Unit of measurement: units on a scale

6. Number of participants with incidence of injection site reactions (ISRs) recorded through the CRF during the AE reporting period (defined as from screening to 85 days after the dose of study drug)

   Analysis Population: SAP included all participants who received at least 1 dose of gantenerumab, whether or not they had prematurely withdrawn from the study

   Table 7: Injection-site reaction

	Gantenerumab 510 mg (N=20) n (%)
Local injection reaction	13 (65.0)

Systemic injection reaction	0

Unit of measurement: participants

7. Number of participants with anti-drug antibodies (ADAs) to gantenerumab measured using enzyme linked immunosorbent assay (ELISA) on baseline and Day 85

   Analysis Population: Immunogenicity analysis population included all participants with at least 1 ADA assessment

   Table 8: Baseline Prevalence and Post-baseline Incidence of ADAs to Gantenerumab

	Gantenerumab 510 mg (N=20) n (%)
Baseline evaluable population	20
Baseline prevalence of ADAs	0
Post-baseline evaluable population	19
Post-baseline incidence of ADA	
Treatment-induced ADAs	1 (5.3)
Treatment-enhanced ADAs	0

Unit of measurement: participants

Secondary Outcome Measures

1. Area under the concentration–time curve of gantenerumab measured using noncompartmental analysis from time 0 to 672 hours [AUC(0-672)], at pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 8, 12, 21, 29, 43, 64 and 85

   Analysis Population: PKAP included all participants who received a single SC dose of gantenerumab and who had evaluable PK data with no relevant protocol deviations with respect to the PK endpoints

   Table 9: Summarized Gantenerumab AUC(0-672)

Treatment	**Number of Participants Analysed**	**Geometric Mean**	**Geometric Coefficient of Variation**
AUC(0-672)	20	13290	43.43

Unit of measurement: µg*h/mL

2. Area under the concentration–time curve of gantenerumab from time 0 to the time of the last quantifiable concentration [AUC(0-last)] measured using noncompartmental analysis at pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 8, 12, 21, 29, 43, 64 and 85

   Analysis Population: PKAP included all participants who received a single SC dose of gantenerumab and who had evaluable PK data with no relevant protocol deviations with respect to the PK endpoints

   Table 10: Summarized Gantenerumab AUC(0-last)

Treatment	Number of Participants Analysed	Geometric Mean	Geometric Coefficient of Variation
AUC(0-last)	20	20130	39.38

Unit of measurement: µg*h/mL

3. Apparent terminal elimination half-life (t1/2) of gantenerumab measured using noncompartmental analysis at pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 8, 12, 21, 29, 43, 64 and 85

   Analysis Population: PKAP included all participants who received a single SC dose of gantenerumab and who had evaluable PK data with no relevant protocol deviations with respect to the PK endpoints

   Table 11: Summarized Gantenerumab t1/2

Treatment	Number of Participants Analysed	Median	Minimum - Maximum
t1/2	19	455.7	327 - 594

Unit of measurement: hour (h)

4. Apparent systemic clearance (CL/F) after SC dosing of gantenerumab measured using noncompartmental analysis at pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 8, 12, 21, 29, 43, 64 and 85

   Analysis Population: PKAP included all participants who received a single SC dose of gantenerumab and who had evaluable PK data with no relevant protocol deviations with respect to the PK endpoints

   Table 12: Summarized Gantenerumab CL/F

Treatment	Number of Participants Analysed	Geometric Mean	Geometric Coefficient of Variation
CL/F	19	0.02359	40.13

Unit of measurement: litres per hour (L/h)

5. Apparent volume of distribution following SC dosing of gantenerumab based on the terminal phase (Vz/F) measured using noncompartmental analysis at pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 8, 12, 21, 29, 43, 64 and 85

   Analysis Population: PKAP included all participants who received a single SC dose of gantenerumab and who had evaluable PK data with no relevant protocol deviations with respect to the PK endpoints

   Table 13: Summarized Gantenerumab Vz/F

Treatment	Number of Participants Analysed	Geometric Mean	Geometric Coefficient of Variation
Vz/F	19	15.36	40.82

Unit of measurement: litres (L)

6. Time to maximum observed plasma concentration (tmax) of gantenerumab measured using noncompartmental analysis at pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 8, 12, 21, 29, 43, 64 and 85

   Analysis Population: PKAP included all participants who received a single SC dose of gantenerumab and who had evaluable PK data with no relevant protocol deviations with respect to the PK endpoints

   Table 14: Summarized Gantenerumab tmax

Treatment	Number of Participants Analysed	Median	Minimum - Maximum
tmax	20	119.980	96.08 - 265.83

Unit of measurement: h

7. Apparent terminal rate constant (λz) of gantenerumab measured using noncompartmental analysis at pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 8, 12, 21, 29, 43, 64 and 85

Analysis Population: PKAP included all participants who received a single SC dose of gantenerumab and who had evaluable PK data with no relevant protocol deviations with respect to the PK endpoints

Table 15: Summarized Gantenerumab λz

Treatment	Number of Participants Analysed	Geometric Mean	Geometric Coefficient of Variation
λz	19	0.001536	13.53

Unit of measurement: per hour (1/h)

Adverse Events

Table 16: Adverse Events by System Organ Class and Preferred Term

System Organ Class	Preferred Term	Gantenerumab 510 mg (N=20) n (%)
General disorders and administration site conditions	Injection site haemorrhage	9 (45.0)
	Injection site erythema	5 (25.0)
Investigations	Urobilinogen urine increased	2 (10.0)
	Blood creatine phosphokinase increased	1 (5.0)
Respiratory, thoracic, and mediastinal disorders	Cough	1 (5.0)